Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Jumped In...

<< Previous

Bullboard Posts

Next >>

Comment by KILOFINALon Mar 06, 2021 7:31am

320 Views

Post# 32735575

RE:RE:RE:Jumped In...

that's the plan!

PowerofNow wrote: Anyone holding over 500k shares is setting themselves up for an early retirement if held to $1.

PTBailey wrote: Totally agree. I have been accumilating over last couple years and hoping to add anotgher 100K this week. Very excited about the potential of this company and the product.